Predictors of Response and Rational Combinations for the Novel 1

MCL-1 Inhibitor MIK665 in Acute Myeloid Leukemia 2

Running title: Stratifying AML Patients for MCL-1 Inhibition 3

Authors: 4

- Joseph Saad¹, Rhiannon Newman^{1*}, Elmira Khabusheva^{1*}, Sofia Aakko¹, Eric 5
- Durand², Mahesh Tambe¹, Heikki Kuusanmäki¹, Alun Parsons¹, Juho J. Miettinen¹, 6
- Komal Kumar Javarappa¹, Nemo Ikonen¹, Mika Kontro^{1,3,4}, Kimmo Porkka³, Heiko 7
- Maacke², Janghee Woo⁵, Ensar Halilovic⁶, Caroline A. Heckman¹ 8

9

Affiliations: 10

- ¹ Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science 11
- (HiLIFE), iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, 12
- Helsinki, Finland 13
- 14 ² Novartis Biomedical Research, Basel, Switzerland
- ³ Department of Hematology, Helsinki University Hospital Comprehensive Cancer 15
- Center, Helsinki, Finland 16
- ⁴ Foundation for the Finnish Cancer Institute, Helsinki, Finland 17
- ⁵ Winship Cancer Institute of Emory University, Atlanta, GA, USA 18
- ⁶ Novartis Biomedical Research, Cambridge, MA, USA 19
- * RN and EK contributed equally to this study. 20

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

21 Correspondence:

- 22 Caroline Heckman, PhD
- 23 Institute for Molecular Medicine Finland (FIMM)
- 24 University of Helsinki
- 25 P.O. Box 20 (Tukholmankatu 8)
- 26 00014 Helsinki, Finland
- 27 Phone: +358 29 4125769; email: caroline.heckman@helsinki.fi

28

29 Competing interests:

Sofia Aakko is currently an employee of Faron Pharmaceuticals, and Eric Durand is 30 an employee of Owkin. During their participation in this study. Eric Durand, Janghee 31 32 Woo, Heiko Maacke, and Ensar Halilovic were employees and shareholders of Novartis. Caroline Heckman received research funding from Novartis related to this 33 work and has received unrelated research funding from BMS/Celgene, Kronos Bio, 34 Oncopeptides, Orion Pharma, WntResearch, and the Innovative Medicines Initiative 2 35 project HARMONY, plus personal fees from Amgen and Autolus. Mika Kontro has 36 received personal fees from Astellas Pharma, AbbVie, Bristol-Myers Squibb, Faron 37 Pharmaceuticals, Novartis and Pfizer outside the submitted work. Kimmo Porkka has 38 received unrelated research funding from Incyte, Novartis and Roche. 39

- 40 Title: 111/150 characters
- 41 **Abstract:** 200/200 words
- 42 **Text:** 4264/4000 words
- 43 Figures, tables: 7/8
- 44 **References**: 44/60

45 **Abstract**

Despite promising anti-leukemic activity of MCL-1 inhibitors in preclinical studies of 46 acute myeloid leukemia (AML), their progress through clinical evaluation has in part 47 been challenged by limited knowledge of patient subgroups suitable for treatment. To 48 stratify patients with AML for MCL-1 inhibitor-based treatment, we evaluated the 49 sensitivity of 42 primary AML samples to MCL-1 inhibitor MIK665 (S64315) and 50 contrasted their molecular profiles. We observed that MIK665 sensitive samples had 51 52 a more differentiated phenotype, whereas resistant samples displayed higher levels of ABCB1 (MDR1) and the anti-apoptotic protein BCL-XL. Further evaluation revealed 53 that ABCB1 expression has good predictive performance in identifying MIK665 54 primary resistant samples. To induce sensitivity, we treated MIK665-resistant samples 55 with ABCB1 inhibitor elacridar, BCL-XL inhibitor A1331852, or BCL-2 inhibitor 56 venetoclax in combination with MIK665. While combinations with elacridar and 57 A1331852 were not effective, the combination of MIK665 and venetoclax effectively 58 eliminated AML blasts compared to either of the agents alone. Additionally, the 59 combination restored sensitivity of samples with primary venetoclax resistance. 60 Overall, this study indicates that elevated *ABCB1* expression is a potential predictor 61 of resistance to MIK665 in AML, and that a combination of MIK665 with venetoclax 62 may be effective for overcoming resistance to either MCL-1 or BCL-2 inhibition. 63

64 Introduction

Of the several novel targeted therapies recently approved for the treatment of acute 65 myeloid leukemia (AML), the combinations of azacitidine or low dose cytarabine with 66 the BCL-2 inhibitor venetoclax for newly diagnosed patients unfit for intensive 67 chemotherapy are particularly efficacious for this previously difficult to treat subgroup 68 of patients (1–4). Apoptosis is a tightly regulated molecular process essential for the 69 maintenance of cellular homeostasis, and the deregulation of which is a fundamental 70 71 hallmark of tumorigenesis (5). The dependency of AML blasts on different antiapoptotic BCL-2 family members, such as BCL-2, MCL-1, and BCL-XL, to escape 72 apoptosis mark these proteins as ideal targets for therapeutic inhibition (6). Despite 73 significant improvements in overall survival and remission rates, venetoclax-based 74 therapies are challenged by both primary and acquired resistance leading to relapse 75 (7). This raises the need for novel, rational drug combinations capable of attaining 76 deeper and prolonged responses. 77

In AML, elevated MCL-1 expression plays a central role in escape from apoptosis and 78 has been associated with poor patient prognosis (8,9). As such, inhibitors targeting 79 MCL-1 have been evaluated in preclinical studies alone and in combination with BCL-80 2 inhibitors resulting in encouraging findings (10–13). These results have supported 81 the clinical evaluation of several MCL-1 inhibitors as monotherapies or in combination 82 with BCL-2 inhibitors and hypomethylating agents (14,15). However, the progression 83 of MCL-1 inhibitors towards clinical approval has been hindered by dose-limiting 84 cardiotoxicity and limited knowledge of biomarkers of response (14). Therefore, 85 identification of patient subgroups likely to benefit from MCL-1 inhibition, as well as 86

suitable drug combinations, could improve efficacy and accelerate the development of
this drug class.

89 In this study, we evaluated the activity of the MCL-1 inhibitor MIK665 in AML preclinical models. To identify indicators of response, we assessed the ex vivo sensitivity of 42 90 AML samples to MIK665 and compared the transcriptional and protein expression 91 92 profiles of MIK665 sensitive and resistant samples. The drug response groups were clearly distinguished by disease maturation phenotype and specific gene expression 93 patterns. Additionally, we found that ABCB1 expression is a predictive indicator of 94 95 MIK665 resistance in AML samples. We also identified the combination of MIK665 and venetoclax as an effective strategy to overcome resistance to either agent in AML cell 96 lines and samples. This study uncovers novel response patterns to MIK665 in AML 97 that could aid the identification of patients that would benefit from MCL-1 inhibitor-98 based therapy and improve outcome. 99

100 Materials and Methods

101 **Patient samples**

Bone marrow (BM) aspirates and matched skin biopsies from patients with AML 102 (n=42), as well as healthy BM control samples (n=2), were collected from the Helsinki 103 University Hospital or the Finnish Hematology Registry and Biobank following written 104 informed consent, according to protocols approved by the local ethics committee 105 (permit numbers 239/13/03/00/2010 and 303/13/03/01/2011), and in compliance with 106 the Declaration of Helsinki. BM mononuclear cells (MNCs) were isolated by Ficoll 107 density gradient centrifugation (GE Healthcare, Buckinghamshire, UK) and suspended 108 in conditioned medium (CM: RPMI 1640, 12.5% HS-5 conditioned medium, 10% fetal 109 bovine serum (FBS), 2 mM L-glutamine, 100 units/ml penicillin and 100 µg/ml 110 streptomycin) (16). All AML samples contained at least 50% malignant MNCs. RNA 111 from the BM MNCs was prepared using the AllPrep DNA/RNA/miRNA Universal kit or 112 miRNeasy mini kit (Qiagen, Hilden, Germany), and then subjected to RNA sequencing 113 as previously described (17). Remaining MNCs from the samples were viably 114 cryopreserved for further experiments. The clinical characteristics of the AML patient 115 samples used are summarized in Table 1. 116

117 Multiparamteric flow cytometry-based drug testing of patient samples

Viably cryopreserved AML and healthy MNCs were thawed, treated with DNase I, and suspended in CM for *ex vivo* drug testing. All samples were tested with MCL-1 inhibitors MIK665 and S63845, and BCL-2 inhibitor venetoclax. The drugs were dissolved in DMSO and pre-plated on 96-well V-bottom plates (Thermo Fisher Scientific, Carlsbad, CA) in 7 increasing concentrations from 0.1 to 1000 nM using an

Echo 550 acoustic liquid handler (Labcyte, San Jose, CA, USA). Cells were incubated 123 on the drug plates for 48 h at 37 °C in 5% CO₂. Following initial profiling, selected AML 124 samples (n=9) were taken forward for drug combination testing of MIK665 combined 125 with venetoclax, ABCB1 inhibitor elacridar, or BCL-XL inhibitor A1331852. Each drug 126 was tested in 6 increasing concentrations from 1 and 1000 nM, while the other drug 127 was fixed at 30 nM (Supplementary Figure 1). When the number of cells from a patient 128 129 sample was insufficient, the combination of MIK665 in increasing concentrations with the other drug fixed at 30 nM was prioritized. Following incubation with the drugs, cells 130 131 were stained with an antibody panel designed for the identification of myeloid cell populations (Supplementary Table 1). Afterwards, the plates were analyzed using flow 132 cytometry on the iQue Screener PLUS (Intellicyt, Albuquerque, NM, USA) and gating 133 was performed using the ForeCyt software (Intellicyt). All drugs used in single agent 134 and combination screens are summarized in Supplementary Table 2. The gating 135 strategy used is illustrated in Supplementary Figure 2. 136

137 Cell line expression and dependency analysis

Publicly available data was downloaded from DepMap portal and analyzed in GraphPad Prism. Gene expression data was available for 45 myeloid leukemia cell lines, and dependency data for 24 myeloid leukemia cell lines. A low Chronos score corresponds to a high gene dependency. Visualization of *BCL2*, *BCL2L1*, and *MCL1* expression and dependency was made for 24 cell lines which had both data sets available.

144 Cell line culture

145 HEL, HL-60, MOLM-13, and Kasumi-1 cell lines were purchased from DSMZ 146 (Braunschweig, Germany). MV4-11 cell line was purchased from ATCC (Manassas,

VA, USA). HEL, Kasumi-1 and MV4-11 were maintained in RPMI 1640 medium
supplemented with 10-20% heat-inactivated FBS, L-glutamine (2 mM), penicillin (100
U/mL), and streptomycin (100 mg/mL). All cells were maintained at 37 °C in 5% CO₂.

150 Generation of venetoclax-resistant (VenR) cell lines

Kasumi-1, MV4-11, MOLM-13, and HL-60 cells were exposed to increasing concentrations of venetoclax (from 12.5 nM – 1000 nM) with the drug concentration being doubled every 2 days, as previously described (18). VenR cell lines were derived from parental cells that continued to proliferate in the presence of 1000 nM of venetoclax.

156 Knockout of ABCB1 in HEL cells using CRISPR/Cas9

gRNA ENSE00003398270 The targeting of ABCB1 (5' 157 exon AAGTCCAGCCCCATGGATGA-3') was inserted into the lentiCRISPRv2GFP vector 158 following the protocol as previously described by the Zhang lab (19). Lentiviral 159 particles were generated by transfection of second-generation lentiviral systems into 160 HEK293-FT cells by calcium phosphate transfection (Promega, Madison, WI, USA). 161 The viral suspension was used to transduce HEL cells for 5 days at 37 °C and 5% 162 CO₂. Following this, fluorescence-activated cell sorting of GFP-positive cells into 96-163 well plates was carried out using the BD Influx cell sorter (Franklin Lakes, NJ, USA). 164 Cells were maintained in 100 µl of complete RPMI media per well and expanded when 165 needed. PCR was used to identify ABCB1 knockout, which was confirmed by sanger 166 sequencing and western blotting. 167

168 CellTiterGlo-based drug testing of cell lines

Cell lines were tested with MIK665 and venetoclax as single agents or in combination in a range of 5 increasing concentrations from 6.25 to 100 nM (Supplementary Figure 3). The compounds were added to a 384-well plate using an acoustic liquid handling device Echo 550 (Labcyte). All cell lines were incubated on the drug plates at 37 °C and 5% CO₂ for 48 h. Cell viability was measured by adding 25 µl of CellTiter-Glo reagent (Promega) to each well and luminescence signal read using a PHERAstar plate reader (BMG Labtech, Ortenberg, Germany).

176 Data Analysis

For drug response assessment, viability readouts from drug treated wells were normalized to negative (DMSO) and positive (benzathonium chloride) controls, and inhibition dose-response curves were generated for each sample and treatment. Consequently, the modified integration of these curves yielded a drug sensitivity score (DSS) as previously described (20). The DSS is directly proportional to the response of a sample to a drug and has a range of 0 to 50. For drug combination synergy readouts, SynergyFinder 2.0 was used for the calculation of ZIP synergy scores (21).

Bulk RNA sequencing for AML patient samples was analyzed in-house as previously described, yielding a gene-sample raw count matrix (17,22). Trimmed Mean of M values (TMM) normalization was performed using the edgeR package and counts per million (CPM) values were computed (23). Differential gene expression analysis was performed using a limma-voom pipeline for regression modeling, identifying differentially expressed genes (FDR < 0.1) (24).

Confirmatory data analyses were performed using publicly available AML patientsample datasets: TCGA and BEAT AML (25,26).

All statistical tests were performed using R software (R version 4.0.0), and nonparametric tests used in cases where the normality of distribution by the Shapiro-Wilk test was not verified. Two group-comparisons were done by the 2-sample t-test or by the Mann Whitney U-test. Correlations between two continuous sets of values were performed using the Pearson or the Spearman method. Multiple testing correction by the Benjamini-Hochberg method was performed when applicable.

Data Availability Statement

RNA sequencing data of AML samples is available in Supplementary Table 3, and drug
sensitivity testing results from the single agent screen is available in Supplementary
Table 6. For other original data, please contact the corresponding author.

For more detailed descriptions of the methodology, see the Supplementary Materials and Methods section. For the full list of western blot antibodies and RT-qPCR primers used, see Supplementary Tables 4 and 5.

206 **Results**

207 Primary AML cells display variable response to MIK665

Dose response of AML samples (n=42) to MCL-1 inhibitor MIK665 was assessed using 208 a multiparametric flow cytometry-based assay. The leukocyte cell viability dose-209 response curve of each sample was converted into a drug sensitivity score (DSS), 210 directly proportional to the sample's response to MIK665 (Figure 1A). AML leukocyte 211 populations demonstrated a DSS continuum across the samples, ranging from 5.2 to 212 34.9. Based on the DSS distribution, we selected DSS cutoffs of 10 and 20 to 213 represent resistant (n=10) and sensitive (n=15) samples, respectively. The remaining 214 17 samples were defined as intermediate responders (Figure 1B). The effect of 215 MIK665 on the leukocytes of a sensitive and a resistant AML sample is illustrated in 216 Supplementary Figure 4. In parallel, S63845, an MCL-1 inhibitor structurally related to 217 MIK665, was also tested in the samples resulting in a similar response pattern to 218 MIK665 (Supplementary Figure 5) (27). The full list of results obtained from the single 219 agent screening experiments is available in Supplementary Table 6. 220

221 Viability dose-response curves for leukocyte (CD45+), blast (CD45dim-sidescatter low), monocyte (CD14+) and lymphocyte (CD45high-sidescatter low) subpopulations 222 are illustrated in Figures 1C-F. Of the 42 AML samples, 16 contained a quantifiable 223 monocytic population (representing \geq 5% of the total leukocytes), 75% (n=12) of which 224 were sensitive to MIK665 (Figure 1E). 23 out of the 42 samples contained a 225 quantifiable lymphocyte population, 96% (n=22) of which were not sensitive to the 226 treatment (Figure 1F). Additionally, MIK665 was tested on BM MNCs from 2 healthy 227 donors. Intermediate DSS values (10 and 12) were observed for the leukocyte 228 populations, with the lymphocyte populations showing similar responses, further 229

indicating that MIK665 has a limited effect on healthy hematopoietic cells (Figure 1GH). Together, these data indicated that MIK665 was particularly effective in AML cells
differentiated towards the monocytic lineage, while its effect on lymphocytes was
limited.

High expression of ABCB1 or BCL-XL is associated with resistance to MIK665

To identify molecular indicators distinguishing MIK665-sensitive (n=15) and resistant (n=10) samples, we performed differential gene expression analysis. The genes analyzed were restricted to protein-coding genes having sufficiently high expression level (Supplementary Materials and Methods). 112 genes were differentially expressed (FDR < 0.1), 74 of which were upregulated and 38 were downregulated in MIK665resistant compared to sensitive samples (Figure 2A, Supplementary Table 7).

ABCB1 was among the most enriched genes in the resistant samples, with a log2 fold 241 242 change of -3.54 (Figure 2A). Encoding the multi-drug resistance protein MDR1, also known as P-gp, ABCB1 is associated with multi-class drug resistance in a range of 243 cancers (28). ABCB1 expression level was significantly upregulated in MIK665-244 resistant samples compared to both intermediate and sensitive samples 245 (Supplementary Figure 6A). Across the samples, *ABCB1* expression was significantly 246 inversely correlated to MIK665 DSS, indicating that ABCB1 expression can be used 247 as a marker of MIK665 resistance (Figure 2B). The difference in expression of ABCB1 248 between the highest and lowest expressing samples was validated by RT-qPCR 249 250 (Supplementary Figure 7, Supplementary Methods). To confirm ABCB1 expression at the protein level, we performed western blotting on a set of 12 samples (8 with low 251 ABCB1 and 4 with high ABCB1 RNA expression). In concordance with the 252 253 transcriptomic data, elevated levels of ABCB1 were detected in MIK665-resistant, but

not in sensitive samples (Figure 2D, Supplementary Figure 8, SupplementaryMethods).

256 Of the BCL-2 family members, BCL2L1, encoding the anti-apoptotic protein BCL-XL, had the highest expression in the resistant samples (Figure 2A, Supplementary Figure 257 6B). As with ABCB1, we detected a significant inverse correlation between BCL2L1 258 expression and MIK665 DSS (Figure 2C). Interestingly, BCL2L1 levels positively 259 correlated with ABCB1 levels in our sample cohort, a finding we confirmed in two 260 publicly available datasets: BEAT and TCGA (Supplementary Figure 6C-E). Western 261 blot analysis showed higher BCL-XL protein expression in MIK665-resistant compared 262 to sensitive samples in our cohort. BCL-2 and MCL-1 levels varied across the sensitive 263 264 and resistant samples, indicating that neither was linked to primary MIK665 resistance (Figure 2D, Supplementary Figure 8). 265

Together, these results indicate that high ABCB1 and high BCL-XL levels are useful indicators of MIK665 resistance and could constitute potential mechanisms of resistance to the drug in AML.

Differentiation markers *LILRA2* and *IL17RA* are associated with MIK665 sensitivity

Differential gene expression analysis showed *LILRA2* and *IL17RA*, encoding leukocyte immunoglobulin-like and low affinity interleukin 17A receptors, respectively, to be among the top upregulated genes in MIK665-sensitive samples, with significantly higher expression levels compared to the intermediate and resistant samples (Figure 2A). In line with this finding, expression values of both genes were significantly correlated with MIK665 DSS values (Supplementary Figure 9A-D). Similar to *MCL1*, *LILRA2* and *IL17RA* are known to be associated with hematopoietic cell differentiation,

notably monocytic and polymorphonuclear lineages (Supplementary Figure 10). To 278 study the implications of this expression pattern on MIK665 sensitivity, we compared 279 MIK665 response levels in our cohort across differentiation subtypes based on the 280 French-American-British (FAB) classification. AML samples with a more differentiated 281 cellular phenotype (FAB M4 or M5) were generally more sensitive to MIK665 282 compared to immature samples (FAB M0/M1 or M2), even though a small subset of 283 284 less differentiated samples was also responsive (Supplementary Figure 9E). These findings suggest that more differentiated AML phenotypes, characterized by high 285 286 *LILRA2* and *IL17RA* expression, are more likely to be sensitive to MCL-1 inhibition by MIK665, in line with our observation that MIK665 is more effective in monocytic 287 populations. 288

AML cell lines with high ABCB1 expression demonstrate distinct dependency patterns on BCL-2 family members

To further investigate potential relationships between ABCB1 and BCL2 family anti-291 apoptotic genes, we analyzed gene expression (n=45) and dependency data (n=24) 292 293 of AML cell lines (Figure 3A and 3B; Supplementary Figure 11). Cell lines were categorized as having a high (log2CPM > 2) or low (log2CPM < 2) ABCB1 expression, 294 and the two groups were contrasted for their expression of and dependence on BCL2. 295 *MCL1*, and *BCL2L1*. AML cell lines with high *ABCB1* expression had significantly 296 reduced BCL2 and significantly increased BCL2L1 expression compared to the cell 297 lines with low ABCB1 level, while no difference in the MCL1 expression was detected 298 299 between the two groups (Figure 3C). Concordantly, AML cell lines with high ABCB1 expression demonstrated significantly higher dependency on BCL2L1, as well as 300 significantly reduced BCL2 and MCL1 dependency (Figure 3D). Together, these 301

findings suggest that AML cell lines exhibiting elevated *ABCB1* expression are more
 dependent on BCL-XL than on MCL-1 or BCL-2 for survival.

304 ABCB1 expression is a strong predictive biomarker of MIK665 resistance

To evaluate the predictive effect of ABCB1 expression on MIK665 response in AML 305 samples, we plotted the distribution of ABCB1 expression values across the response 306 subgroups in our cohort. The density curves of expression per subgroup showed 307 distinct peaks, with the biggest separation difference between the resistant subgroup 308 compared to the sensitive and intermediate subgroups (Figure 4A, Supplementary 309 Figure 6A). We then performed a receiver operating characteristics (ROC) curve 310 analysis to assess the ability of ABCB1 expression to distinguish MIK665-resistant 311 from sensitive and intermediate samples. The cutoff with the optimal classifying 312 performance for ABCB1 expression was 5.22 (log2CPM) as identified using the 313 Youden index. This resulted in an area under the ROC curve of 0.856, with a sensitivity 314 of 80%, a specificity of 90.6%, and a positive predictive value of 72.7% (Figure 4B-C). 315

316 ABCB1 inhibition does not overcome MIK665 resistance

As ABCB1 is a known driver of multidrug resistance across several cancer types, we 317 sought to evaluate its role as a potential target in MIK665 resistant AML. We selected 318 three ABCB1 high (MIK665 DSS < 15) and three ABCB1 low (MIK DSS > 35) samples 319 and tested these with the ABCB1 inhibitor elacridar in combination with MIK665. The 320 combination of elacridar and MIK665 did not result in significantly higher responses in 321 the ABCB1 high samples, compared to either agent alone (Figure 4D). To further 322 explore if ABCB1 inhibition can restore sensitivity to MIK665, we tested the MIK665 323 and elacridar combination in the HEL AML cell line. The HEL cell line was selected due 324 to its high ABCB1 expression level and was therefore expected to be resistant to MCL-325

1 inhibition by MIK665 (Figure 3A). However, HEL cells did not respond to either drug 326 individually or in combination, indicating that chemical inhibition of ABCB1 cannot 327 restore sensitivity to MCL-1 inhibition by MIK665. To mechanistically investigate the 328 role of ABCB1 in MIK665 resistance, we generated a HEL ABCB1 knockout cell line 329 using CRISPR-Cas9 (Figure 4E). Upon testing of MIK665 in the HELABCB1 knockout 330 cells, drug sensitivity was not increased when compared with HEL parental and HEL 331 332 non-target control (Figure 4F). Overall, we conclude that ABCB1 targeting cannot reverse MIK665 resistance, however, elevated ABCB1 expression serves as a 333 334 predictive biomarker of MIK665 resistance in AML.

MIK665 combined with venetoclax is an effective combination in AML samples with primary resistance to either of the single agents

To evaluate whether co-targeting other anti-apoptotic proteins is effective in MIK665-337 resistant samples, we tested combinations of MIK665 with BCL-XL inhibitor A-338 1331852 or BCL-2 inhibitor venetoclax. The combination of MIK665 and A-1331852 339 did not result in increased sensitivity of the MIK665-resistant samples compared to 340 treatment with MIK665 alone, indicating that co-targeting of BCL-XL and MCL-1 does 341 not restore MIK665 sensitivity (Supplementary Figure 12). However, all three MIK665-342 resistant samples had significantly higher DSS values to the MIK665 and venetoclax 343 combination compared to MIK665 alone, which suggest that targeting both MCL-1 and 344 BCL-2 is an effective strategy to overcome resistance to MIK665 (Figure 5A). 345 Interestingly, we noticed that one of the MIK665-resistant samples that responded well 346 to the combination also had ex vivo primary resistance to venetoclax. To further assess 347 the potential use of this combination in the context of primary venetoclax resistance, 348 additional samples with primary venetoclax 349 we tested three resistance

(Supplementary Figure 5, Supplementary Table 6). The combination showed significantly higher DSS values in all three samples compared to venetoclax alone (Figure 5A). The venetoclax dose-response curves with MIK665 fixed at 30 nM further illustrated the benefit of the addition of MIK665 to venetoclax in these samples (Figure 5B). Together, these results demonstrate that a combination of MIK665 and venetoclax is an efficacious strategy to overcome primary resistance to either of the two agents.

356 MIK665 combined with venetoclax restores sensitivity in AML cell lines with 357 acquired venetoclax resistance

As acquired resistance to venetoclax is commonly observed following venetoclax-358 based treatment, we tested the MIK665 and venetoclax combination in AML cell line 359 models with acquired venetoclax resistance. We generated VenR cell lines MV4-360 11 VenR, Kasumi-1 VenR, MOLM-13 VenR and HL-60 VenR by exposing parental 361 cell lines to increasing concentrations of venetoclax. In all VenR cell lines, MIK665 in 362 combination with venetoclax restored sensitivity. The combination showed high 363 364 synergy in all cell lines, with a greater effect in MV4-11 VenR and MOLM-13 VenR (Figure 6A). Comparison of BCL-2 family protein levels of parental and VenR cell lines 365 showed a trend towards a decrease in BCL-2 expression and an increase in BCL-XL 366 expression upon acquired venetoclax resistance (Figure 6B). These findings show that 367 MIK665 restores sensitivity to venetoclax in AML with acquired venetoclax resistance, 368 indicating the potential clinical relevance of this combination upon patient relapse to 369 venetoclax-based treatment regimens. 370

371 **Discussion**

Our assessment of MCL-1 inhibitor MIK665 activity in primary AML patient samples 372 resulted in varied responses, reflecting the heterogeneous response observed in 373 clinical trials (14,15). ABCB1 was among the most significantly upregulated genes in 374 the MIK665-resistant samples, and logistic regression and ROC curve analyses 375 revealed a strong performance of ABCB1 expression in identifying MIK665-resistant 376 samples. Nonetheless, direct ABCB1 inhibition did not reverse MIK665 resistance. 377 378 Instead, co-inhibition of MCL1 and BCL2 by the addition of venetoclax proved to be an effective strategy in the MIK665-resistant population. 379

ABCB1, commonly referred to as multidrug resistance protein 1 (MDR1) or P-380 glycoprotein (P-gp), can confer resistance to several cancer therapeutics (29). Our 381 previous research has demonstrated that ABCB1-mediated drug efflux represents a 382 resistance mechanism to MCL-1 inhibitors in multiple myeloma (30). In AML, the 383 chemotherapeutic daunorubicin is a known ABCB1 substrate, and high ABCB1 384 expression is enriched in adverse European LeukemiaNet (ELN) risk subgroups with 385 poor outcome in patients treated with standard chemotherapy (31–33). To determine 386 whether ABCB1 inhibition can overcome MIK665 resistance in AML, we evaluated the 387 efficacy of a combination of MIK665 and third generation ABCB1-specific inhibitor 388 elacridar in samples with high ABCB1 expression and low response to MIK665. 389 However, the combination was not more effective compared to MIK665 alone. This is 390 in line with previous studies showing that ABCB1 expression associates with 391 resistance to intensive chemotherapy in AML patients, but that its co-inhibition does 392 not improve prognosis (33). Furthermore, knockout of ABCB1 using CRISPR-Cas9 in 393 AML cells having a high basal level of ABCB1 expression and resistance to MIK665, 394

did not lead to an increased sensitivity. Together, these data indicate that while ABCB1
does not represent a suitable target to overcome MIK665 resistance, high *ABCB1*expression can be used as a biomarker of *ex vivo* MIK665 resistance in AML.

We found BCL2L1, a gene encoding the anti-apoptotic protein BCL-XL, to be 398 significantly correlated with ABCB1 expression in three AML patient cohorts. Previous 399 research has reported that high levels of BCL-XL correlate with resistance to MCL-1 400 inhibition (13,27,34), a finding also observed in this study's MIK665-resistant patient 401 samples. AML cell line analysis further demonstrated that high ABCB1 expression had 402 significantly higher expression of and dependence on BCL2L1. Kuusanmäki et al. 403 found that high BCL-XL expression was correlated with sensitivity to BCL-XL inhibitors 404 in erythroleukemia (FAB M6/M7) (34). However, in our study MIK665-resistant 405 samples did not respond to the BCL-XL inhibitor A1331852 alone or in combination 406 with MIK665. This is likely due to our cohort lacking samples with M6/M7 phenotypes. 407 408 Further analysis indicated that *ABCB1* and *BCL2L1* were significantly enriched in FAB types M0/M1 and M2 compared to M4 and M5 (Supplementary Figure 13, 409 Supplementary Table 8). Supporting this, samples in our cohort with higher expression 410 levels of LILRA2 and ILI7RA, markers of phenotypically mature monocytic-like AML 411 subtypes (notably M4 and M5), were more sensitive to MCL-1 inhibition by MIK665 412 (35). These results align with earlier studies demonstrating that AML FAB subtypes M4 413 and M5 have higher expression of and dependence on MCL-1 and are thus sensitive 414 to MCL-1 inhibition (36,37). 415

In vitro studies have indicated that MCL-1 inhibitors synergize with BCL-2 inhibitors, namely venetoclax, leading to the evaluation of this combination for AML patients in several clinical trials. (11,13,15). Aligning with these observations, we found that the

combination of MIK665 and venetoclax is effective in samples with MIK665 primary 419 resistance. Interestingly, this combination was also effective in AML samples with 420 primary venetoclax resistance, a finding with important clinical relevance, since up to 421 30% of AML patients treated with venetoclax-based regimens are found to be primary 422 refractory to the treatment (2,38-41). Previous clinical trials have reported cases of 423 disease progression and acquired resistance to venetoclax-based therapies following 424 425 initial remissions in over 50% of patients until time last of follow-up, leaving them with limited treatment options and a dismal prognosis (40,42). Using AML cell lines with 426 427 acquired venetoclax resistance as a model for clinical venetoclax relapse, we observed that the MIK665 and venetoclax combination was also highly effective in this 428 context. This is in line with previous findings showing that MCL1-upregulation 429 contributes to acquired venetoclax resistance, and that the addition of an MCL-1 430 inhibitor has the potential to restore sensitivity (43,44). Overall, the combination of 431 MIK665 and venetoclax was effective in AML patient samples with primary resistance 432 to either of the single agents, as well as AML cell lines with acquired venetoclax 433 resistance, a finding warranting further clinical evaluation. The elevated sensitivity of 434 such AML patient subgroups to the combination of MIK665 and venetoclax suggests 435 that lower treatment doses could be administered, thereby improving toxicity profiles, 436 which have so far represented a major obstacle for MCL-1 inhibitor development. 437

In summary, the associations between diverse molecular features of AML samples and their sensitivity to MIK665 described in this study provide valuable insights from a precision medicine and clinical trial design viewpoint. Our study identifies a sizable target AML patient population with differentiated disease that is susceptible to MCL-1 inhibition by MIK665. Moreover, we show that elevated *ABCB1* expression represents a predictive biomarker of resistance to MIK665, which can be overcome by the addition

- of venetoclax. Our findings support the evaluation of the combination of MIK665 with
- venetoclax in resistant patient populations to restore and prolong clinical responses.

446 Acknowledgements

The authors of this work would like to thank the Finnish Hematology Registry and 447 Clinical Biobank for providing the patient samples and data, the contributing clinicians 448 and nurses, and especially the donors. The authors also acknowledge the FIMM High 449 Throughput Biomedicine Unit for the drug plate preparation, as well as the FIMM 450 Technology Center sequencing and bioinformatics units for preparing and curating the 451 samples' molecular profiles. The units are hosted by the University of Helsinki and are 452 453 supported by HiLIFE and Biocenter Finland. This work is expected to contribute to the fulfillment of the PhD requirements of J.S. and R.N., both doctoral candidates at the 454 University of Helsinki. The authors would like to extend further thanks to Minna Suvela 455 and Siv Knaappila for processing the samples used in the study, and to Lisa Eick for 456 providing input into the biomarker analysis. The authors also appreciate the valuable 457 input and revisions received from colleagues at FIMM, Novartis, the Helsinki University 458 Hospital and Comprehensive Cancer Center and Servier Laboratories. This work was 459 supported by funding received by C.A.H. from Novartis, the Research Council of 460 Finland (grant no. 334781, 352265, 357686, and 320185), the Sigrid Jusélius 461 Foundation, and the Cancer Foundation Finland. 462

463 **Author contributions**

464 J.S., R.N., E.K., S.A., H.K., M.T., A.P., J.M. and K.K. designed and performed the 465 experimental work. J.S., R.N., E.K., N.I., and E.D. carried out the result analysis and 466 interpretation. J.S. and R.N. drafted the manuscript, and all authors contributed to its 467 revision. C.A.H. and E.H. conceived and supervised the study. C.A.H. provided 468 infrastructure to carry out the work.

References 469

470 471 472 473	1.	Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood [Internet]. 2020 Jun 11 [cited 2024 Apr 11];135(24):2137–45. Available from: https://pubmed.ncbi.nlm.nih.gov/32219442/
474 475 476 477	2.	DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med [Internet]. 2020 Aug 13 [cited 2024 Apr 11];383(7):617–29. Available from: https://pubmed.ncbi.nlm.nih.gov/32786187/
478 479 480 481	3.	Bhansali RS, Pratz KW, Lai C. Recent advances in targeted therapies in acute myeloid leukemia. Journal of Hematology & Oncology 2023 16:1 [Internet]. 2023 Mar 25 [cited 2024 Nov 1];16(1):1–27. Available from: https://jhoonline.biomedcentral.com/articles/10.1186/s13045-023-01424-6
482 483 484 485	4.	Totiger TM, Ghoshal A, Zabroski J, Sondhi A, Bucha S, Jahn J, et al. Targeted Therapy Development in Acute Myeloid Leukemia. Biomedicines [Internet]. 2023 Feb 1 [cited 2024 Nov 1];11(2):641. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9953553/
486 487 488	5.	Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell [Internet]. 2011 Mar 4 [cited 2024 Nov 1];144(5):646–74. Available from: http://www.cell.com/article/S0092867411001279/fulltext
489 490 491	6.	Krawiec K, Strzałka P, Czemerska M, Wiśnik A, Zawlik I, Wierzbowska A, et al. Targeting Apoptosis in AML: Where Do We Stand? Cancers (Basel) [Internet]. 2022 Oct 1 [cited 2024 Nov 1];14(20). Available from: https://pubmed.ncbi.nlm.nih.gov/36291779/
492 493 494	7.	Garciaz S, Hospital MA, Collette Y, Vey N. Venetoclax Resistance in Acute Myeloid Leukemia. Cancers 2024, Vol 16, Page 1091 [Internet]. 2024 Mar 8 [cited 2024 Nov 1];16(6):1091. Available from: https://www.mdpi.com/2072-6694/16/6/1091/htm
495 496 497 498	8.	Glaser SP, Lee EF, Trounson E, Bouillet P, Wei A, Fairlie WD, et al. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev [Internet]. 2012 Jan 15 [cited 2024 Nov 1];26(2):120. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC3273836/
499 500 501 502	9.	Li XX, Zhou JD, Wen XM, Zhang TJ, Wu DH, Deng ZQ, et al. Increased MCL-1 expression predicts poor prognosis and disease recurrence in acute myeloid leukemia. Onco Targets Ther [Internet]. 2019 [cited 2024 Nov 1];12:3295. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC6503339/
503 504 505	10.	Szlavik Z, Csekei M, Paczal A, Szabo ZB, Sipos S, Radics G, et al. Discovery of S64315, a Potent and Selective Mcl-1 Inhibitor. J Med Chem [Internet]. 2020 Nov 25 [cited 2024 Nov 1];63(22):13762–95. Available from: https://pubmed.ncbi.nlm.nih.gov/33146521/
506 507	11.	Ramsey HE, Fischer MA, Lee T, Gorska AE, Arrate MP, Fuller L, et al. A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous

508 509		Leukemia. Cancer Discov [Internet]. 2018 Dec 1 [cited 2024 Nov 1];8(12):1566–81. Available from: https://pubmed.ncbi.nlm.nih.gov/30185627/
510 511 512 513	12.	Tron AE, Belmonte MA, Adam A, Aquila BM, Boise LH, Chiarparin E, et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat Commun [Internet]. 2018 Dec 1 [cited 2024 Nov 1];9(1). Available from: https://pubmed.ncbi.nlm.nih.gov/30559424/
514 515 516 517 518	13.	Caenepeel S, Brown SP, Belmontes B, Moody G, Keegan KS, Chui D, et al. AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies. Cancer Discov [Internet]. 2018 Dec 1 [cited 2024 Nov 1];8(12):1582–97. Available from: https://pubmed.ncbi.nlm.nih.gov/30254093/
519 520 521	14.	Tantawy SI, Timofeeva N, Sarkar A, Gandhi V. Targeting MCL-1 protein to treat cancer: opportunities and challenges. Front Oncol [Internet]. 2023 [cited 2024 Jul 4];13. Available from: /pmc/articles/PMC10436212/
522 523 524 525	15.	Wei AH, Roberts AW, Spencer A, Rosenberg AS, Siegel D, Walter RB, et al. Targeting MCL-1 in hematologic malignancies: Rationale and progress. Blood Rev [Internet]. 2020 Nov 1 [cited 2024 Apr 11];44. Available from: https://pubmed.ncbi.nlm.nih.gov/32204955/
526 527 528 529	16.	Karjalainen R, Pemovska T, Popa M, Liu M, Javarappa KK, Majumder MM, et al. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. Blood [Internet]. 2017 Aug 10 [cited 2024 Apr 11];130(6):789–802. Available from: https://pubmed.ncbi.nlm.nih.gov/28619982/
530 531 532 533	17.	Kumar A, Kankainen M, Parsons A, Kallioniemi O, Mattila P, Heckman CA. The impact of RNA sequence library construction protocols on transcriptomic profiling of leukemia. BMC Genomics [Internet]. 2017 Aug 17 [cited 2024 Apr 11];18(1):1–13. Available from: https://bmcgenomics.biomedcentral.com/articles/10.1186/s12864-017-4039-1
534 535 536 537 538	18.	Tambe M, Unterberger S, Kriegbaum MC, Vänttinen I, Olgac EJ, Vähä-Koskela M, et al. Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine. Cell Death & Disease 2024 15:10 [Internet]. 2024 Oct 16 [cited 2024 Nov 1];15(10):1–9. Available from: https://www.nature.com/articles/s41419-024-07140-4
539 540 541 542	19.	Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nature Protocols 2013 8:11 [Internet]. 2013 Oct 24 [cited 2024 Jul 19];8(11):2281–308. Available from: https://www.nature.com/articles/nprot.2013.143
543 544 545 546	20.	Yadav B, Pemovska T, Szwajda A, Kulesskiy E, Kontro M, Karjalainen R, et al. Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Scientific Reports 2014 4:1 [Internet]. 2014 Jun 5 [cited 2024 Apr 11];4(1):1–10. Available from: https://www.nature.com/articles/srep05193
547 548 549	21.	Ianevski A, Giri AK, Aittokallio T. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Res [Internet]. 2020 Jul 2 [cited 2024 Apr 11];48(W1):W488–93. Available from: https://dx.doi.org/10.1093/nar/gkaa216

550 551 552	22.	Kivioja JL, Thanasopoulou A, Kumar A, Kontro M, Yadav B, Majumder MM, et al. Dasatinib and navitoclax act synergistically to target NUP98-NSD1 +/FLT3-ITD+ acute myeloid leukemia. Leukemia. 2019 Jun;33(6):1360–72.	
553 554 555 556	23.	Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics [Internet]. 2010 Nov 11 [cited 2024 Nov 1];26(1):139–40. Available from: https://pubmed.ncbi.nlm.nih.gov/19910308/	
557 558 559 560	24.	Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res [Internet]. 2015 Jan 6 [cited 2024 Apr 11];43(7):e47. Available from: https://pubmed.ncbi.nlm.nih.gov/25605792/	
561 562 563 564	25.	The Cancer Genome Atlas Research Network. Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia. New England Journal of Medicine [Internet]. 2013 May 30 [cited 2024 Nov 1];368(22):2059–74. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa1301689	
565 566 567 568	26.	Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, et al. Functional genomic landscape of acute myeloid leukaemia. Nature 2018 562:7728 [Internet]. 2018 Oct 17 [cited 2024 Jul 20];562(7728):526–31. Available from: https://www.nature.com/articles/s41586-018-0623-z	
569 570 571 572	27.	Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature 2016 538:7626 [Internet]. 2016 Oct 19 [cited 2024 Apr 11];538(7626):477–82. Available from: https://www.nature.com/articles/nature19830	
573 574 575	28.	Skinner KT, Palkar AM, Hong AL. Genetics of ABCB1 in Cancer. Cancers (Basel) [Internet]. 2023 Sep 1 [cited 2024 Nov 1];15(17):4236. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10487083/	
576 577 578 579	29.	Khan SU, Fatima K, Aisha S, Malik F. Unveiling the mechanisms and challenges of cancer drug resistance. Cell Communication and Signaling 2024 22:1 [Internet]. 2024 Feb 12 [cited 2024 Jul 16];22(1):1–26. Available from: https://biosignaling.biomedcentral.com/articles/10.1186/s12964-023-01302-1	
580 581 582 583 584	30.	Bolomsky A, Miettinen JJ, Malyutina A, Besse A, Huber J, Fellinger S, et al. Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma. Blood Adv [Internet]. 2021 Oct 26 [cited 2024 Nov 1];5(20):4125. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC8945627/	
585 586 587	31.	Niu J, Peng D, Liu L. Drug Resistance Mechanisms of Acute Myeloid Leukemia Stem Cells. Front Oncol [Internet]. 2022 Jul 5 [cited 2024 Nov 1];12:896426. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9294245/	
588 589 590 591	32.	Guerci A, Merlin JL, Missoum N, Feldmann L, Marchai S, Witz F, et al. Predictive Value for Treatment Outcome in Acute Myeloid Leukemia of Cellular Daunorubicin Accumulation and P-Glycoprotein Expression Simultaneously Determined by Flow Cytometry. Blood. 1995 Apr 15;85(8):2147–53.	

592 593 594 595	33.	Boyer T, Gonzales F, Barthélémy A, Marceau-Renaut A, Peyrouze P, Guihard S, et al. Clinical Significance of ABCB1 in Acute Myeloid Leukemia: A Comprehensive Study. Cancers (Basel) [Internet]. 2019 Sep 1 [cited 2024 Nov 1];11(9). Available from: https://pubmed.ncbi.nlm.nih.gov/31500210/	
596 597 598 599	34.	Kuusanmäki H, Dufva O, Vähä-Koskela M, Leppä AM, Huuhtanen J, Vänttinen I, et al. Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia. Blood [Internet]. 2023 Mar 30 [cited 2024 Nov 1];141(13):1610–25. Available from: https://dx.doi.org/10.1182/blood.2021011094	
600 601 602 603	35.	Bagger FO, Kinalis S, Rapin N. BloodSpot: a database of healthy and malignant haematopoiesis updated with purified and single cell mRNA sequencing profiles. Nucleic Acids Res [Internet]. 2019 Jan 8 [cited 2024 Nov 1];47(D1):D881–5. Available from: https://pubmed.ncbi.nlm.nih.gov/30395307/	
604 605 606 607 608	36.	Kuusanmäki H, Leppä AM, Pölönen P, Kontro M, Dufva O, Deb D, et al. Phenotype- based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. Haematologica [Internet]. 2020 Mar 1 [cited 2022 May 13];105(3):708–20. Available from: https://haematologica.org/article/view/9289	
609 610 611 612	37.	Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, et al. Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia. Cancer Discov [Internet]. 2020 Apr 1 [cited 2024 Nov 1];10(4):536– 51. Available from: https://pubmed.ncbi.nlm.nih.gov/31974170/	
613 614 615 616	38.	Kuusanmäki H, Kytölä S, Vänttinen I, Ruokoranta T, Ranta A, Huuhtanen J, et al. Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia. Haematologica [Internet]. 2023 Jul 1 [cited 2024 Jul 20];108(7):1768–81. Available from: https://haematologica.org/article/view/haematol.2022.281692	
617 618 619 620	39.	DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood [Internet]. 2019 Jan 3 [cited 2024 Jul 20];133(1):7–17. Available from: https://dx.doi.org/10.1182/blood-2018-08-868752	
621 622 623 624	40.	Pratz KW, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Döhner H, et al. Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol [Internet]. 2024 Apr 1 [cited 2024 Apr 11];99(4). Available from: https://pubmed.ncbi.nlm.nih.gov/38343151/	
625 626 627 628	41.	Kytölä S, Vänttinen IM, Ruokoranta T, Partanen A, Holopainen A, Saad J, et al. Ex Vivo Venetoclax Sensitivity Predicts Clinical Response in Acute Myeloid Leukemia in the Prospective VenEx Trial. Blood [Internet]. 2024 [cited 2024 Nov 1]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/39357056	
629 630 631 632	42.	Stahl M, Menghrajani K, Derkach A, Chan A, Xiao W, Glass J, et al. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Blood Adv [Internet]. 2021 Mar 9 [cited 2024 Nov 5];5(5):1552. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC7948282/	

633	43.	Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H, et al. Activation of RAS/MAPK
634		pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in
635		acute myeloid leukemia. Signal Transduction and Targeted Therapy 2022 7:1 [Internet].
636		2022 Feb 21 [cited 2024 Nov 1];7(1):1–13. Available from:
637		https://www.nature.com/articles/s41392-021-00870-3
638	44.	Moujalled DM, Pomilio G, Ghiurau C, Ivey A, Salmon J, Rijal S, et al. Combining BH3-
639		mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of
640		acute myeloid leukemia. Leukemia [Internet]. 2019 Apr 1 [cited 2024 Nov
641		1];33(4):905–17. Available from: https://pubmed.ncbi.nlm.nih.gov/30214012/
642		

644 Figure Legends

Figure 1. Response of AML bone marrow cell populations to MCL-1 inhibitor 645 **MIK665.** A) An illustration showing the relationship between leukocyte cell viability 646 dose response curves and the drug sensitivity score (DSS). The DSS is a modified 647 area over the cell viability curve, which is directly proportional to the drug sensitivity of 648 a sample. Created with BioRender.com. B) Waterfall plot showing the MIK665 DSS 649 values in leukocytes of AML samples (n=42) in decreasing order. DSS cutoffs were 650 651 used to create sample subgroups based on response to MIK665, such that $DSS \leq 10$ was considered resistant (blue), DSS \geq 20 was considered sensitive (orange), and 10 652 < DSS < 20 was considered intermediate (grey). MIK665 dose-response curves for C) 653 leukocytes (relative IC50 values: 5.4 nM, 45 nM, and 134.8 nM for sensitive, 654 intermediate, and resistant samples, respectively), **D)** blast cells (relative IC50 values: 655 2 nM, 44.1 nM and 158.4 nM respectively), E) monocytes (IC50 values: 3.8 nM, 14.5 656 nM. and 22.9 nM respectively), and F) lymphocytes (IC50 values; 52.6 nM, 97.3 nM, 657 and 84.5 nM respectively). Representative samples with the median DSS from each 658 group are highlighted by thicker lines on the dose-response curves. All cell populations 659 were identified using flow cytometry. MIK665 activity was evaluated in 2 healthy BM 660 samples, resulting in dose-response curves for G) leukocytes (DSS: 10 and 12, IC50: 661 192 nM and 36.4 nM) and H) lymphocytes (DSS: 10.7 and 14.2, IC50: 204.5 nM and 662 32.1 nM). 663

Figure 2. Differential gene expression analysis reveals markers of sensitivity and resistance to MIK665 in AML. A) Volcano plot showing genes analyzed in the differential gene expression analysis. Genes to the left of the vertical line represent those upregulated in the resistant group when compared to the sensitive group,

whereas those to the right of the line are downregulated genes. Genes above the 668 horizontal line (FDR cutoff at 0.1) are significantly differentially expressed (n=112). The 669 labeled genes are ABCB1 (enriched in the resistant samples; logFC = -3.54; FDR = 670 0.041), *LILRA2* (logFC = 2.47; FDR = 0.062) and *IL17RA* (logFC = 1.79; FDR = 0.061) 671 (enriched in the sensitive samples), as well as BCL2, MCL1, and BCL2L1. The full list 672 and statistics of the differentially expressed genes are available in Supplementary 673 674 Table 7. B) Scatterplot showing an inverse correlation between ABCB1 expression and MIK665 DSS in AML samples (n = 42; r = -0.5; p = 0.00071). C) Scatterplot 675 676 showing an inverse correlation between BCL2L1 and MIK665 DSS in AML samples (n = 42; r = -0.4; p = 0.0079). Correlations were performed using the Spearman method. 677 D) Western blot showing the protein expression levels of ABCB1, BCL-2, MCL-1, and 678 BCL-XL in a selection of MIK665-sensitive or resistant AML samples. log2FC: log2 fold 679 change; log2CPM: log2 counts per million; FDR: false discovery rate. 680

681 Figure 3. DepMap analysis of AML cell line data reveals that high ABCB1 and low MCL1 expression are associated with BCL2L1 upregulation and 682 dependency on it. A) Heatmap showing ABCB1, BCL2, MCL1, and BCL2L1 683 expression (log2CPM) in AML cell lines sorted based on ABCB1 expression 684 (log2CPM). B) Heatmap showing dependency (Chronos score) of AML cell lines on 685 BCL2, MCL1, and BCL2L1. Cell line order is based on ABCB1 expression. Boxplots 686 representing BCL2, MCL1, and BCL2L1 C) expression and D) dependency in cell lines 687 with high (purple) and low (grey) ABCB1 levels. Log2CPM \geq 2 was defined as a high 688 689 expression of *ABCB1*, whereas log2CPM < 2 was considered low expression. Each dot represents a single cell line. Significance was evaluated using the 2-sample t-test. 690 691 log2CPM: log2 counts per million.

Figure 4. ABCB1 inhibition in AML with high ABCB1 expression is predictive of 692 **MIK665 resistance.** A) Density curves representing the distribution of ABCB1 693 expression values across the MIK665 response groups. B) Receiver operator 694 characteristic ROC curve of ABCB1 expression as a predictor of MIK665 resistance. 695 The optimal cutoff value for ABCB1 was selected using the Youden index and is 696 indicated by the green dot. C) Contingency matrix showing the performance statistics 697 698 of the test when using an ABCB1 cutoff value of 5.22. Created with BioRender.com. D) Dotplot showing the DSS of MIK665 and ABCB1 inhibitor elacridar alone or in 699 700 combination in AML samples with MIK665 resistance (high ABCB1: log2CPM > 6) or MIK665 sensitivity (low *ABCB1*: log2CPM < 6). Grey dots represent the DSS values 701 of the single agents, whereas red dots represent the DSS values of the combination 702 703 (where one drug is increased along its concentration range while the other is fixed at 30 nM). Significance was evaluated using the paired sample t-test. E) Western blot 704 showing the protein expression level of ABCB1 in HEL ABCB1 knockout (HEL ABCB1 705 KO) cells, as compared to parental and non-target control (NTC) cells. F) Dose-706 response curves of HEL, HELABCB1 knockout and HEL non-target control cells when 707 treated with MIK665 (N=3). Error bars represent the standard deviation. All responses 708 were measured using CellTiter Glo following a 48 h incubation with the drugs. 709 log2CPM: log2 counts per million; AUC: area under the curve. 710

Figure 5. A combination of MIK665 and BCL-2 inhibitor venetoclax is more effective compared to each agent alone in selected AML samples. A) Results showing the DSS of MIK665 and venetoclax alone or in combination in MIK665resistant, MIK665-sensitive and venetoclax-resistant AML samples. MIK665-resistant samples were selected as having high *ABCB1* expression (log2CPM > 6) and a MIK665 DSS < 15. MIK665-sensitive samples were selected as having low *ABCB1*

expression (log2CPM < 6) and a MIK665 DSS > 30. Venetoclax-resistant samples were selected as having a venetoclax DSS < 10. Grey dots represent the DSS values of the single agents, whereas orange or purple dots represent the DSS values of the combinations (where one drug is increased along its concentration range while the other is fixed at 30 nM). All responses are measured following a 48 h incubation with the drugs. Significance was evaluated using the paired sample t-test. **B)** Dose response curves of the 3 venetoclax-resistant patient samples as tested in panel A.

Figure 6. A combination of MIK665 and venetoclax is effective in AML cell lines 724 725 with acquired resistance to venetoclax. A) Dose-response curves of MIK665 and venetoclax alone and in combination in MV4-11 venetoclax-resistant (MV4-11 VenR), 726 Kasumi-1 venetoclax-resistant (Kasumi-1 VenR), MOLM-13 venetoclax-resistant 727 (MOLM-13 VenR) and HL-60 venetoclax-resistant (HL-60 VenR) cell lines, where 728 one drug is increased along its concentration range while the other is fixed at 12.5 nM. 729 730 Responses are measured by CellTiter-Glo following a 48 h incubation. ZIP synergy scores for the combination in each of the cell line are reported in the table. B) Western 731 blot showing the protein expression level of BCL-2, MCL-1, and BCL-XL in parental 732 and VenR cell lines, and the protein quantification normalized to the respective 733 GAPDH levels. 734

		Total (n=42)
Median age (range), years		63 (22-79)
Disease Stage	Diagnosis, n (%)	36 (85.7%)
	Relapse, n (%)	4 (9.5%)
	Refractory, n (%)	2 (4.8%)
Median blast percentage (range)		70.5 (50-95)
FAB	AML M0/1, n (%)	14 (33.3%)
	AML M2, n (%)	8 (19%)
	AML M4, n (%)	3 (7.1%)
	AML M5, n (%)	5 (11.9%)
	NA, n (%)	12 (28.6%)

Table 1. Clinical characteristics of the FIMM AML patient cohort.

FAB, French-American-British classification; NA, data not available

Figure 1. Response of AML bone marrow cell populations to MCL-1 inhibitor 736

MIK665. 737



Figure 2. Differential gene expression analysis reveals markers of sensitivity 739





- Figure 3. DepMap analysis of AML cell line data reveals that high ABCB1 and 742
- low MCL1 expression are associated with BCL2L1 upregulation and 743



A



dependency on it. 744

Figure 4. ABCB1 inhibition in AML with high ABCB1 expression is predictive of 746

MIK665 resistance. 747



Figure 5. A combination of MIK665 and BCL-2 inhibitor venetoclax is more

effective compared to each agent alone in selected AML samples.



В



0-Drug concentration (nM) Drug concentration (nM)

Figure 6. A combination of MIK665 and venetoclax is effective in AML cell lines 752

with acquired resistance to venetoclax. 753

